We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Impax Laboratories, Inc. (delisted) | NASDAQ:IPXL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.30 | 18.30 | 18.55 | 0 | 01:00:00 |
From May 2019 to May 2024
NEW ORLEANS, Dec. 9, 2016 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 9, 2017 to file lead plaintiff applications in a securities class action lawsuit against Impax Laboratories Inc. (NasdaqGS: IPXL), if they purchased the Company's securities between February 20, 2014 through November 3, 2016, inclusive (the "Class Period"). This action is pending in the United States District Court for the Districts of New Jersey and California.
What You May Do
If you purchased securities of Impax and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 9, 2017.
About the Lawsuit
Impax and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies," including Impax, "and about two dozen drugs." The article further stated that a "grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year." Additionally, according to Bloomberg, "[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General."
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
Logo - http://photos.prnewswire.com/prnh/20160819/399590LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--foti-llc-reminds-investors-with-losses-in-excess-of-100000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-impax-laboratories-inc--ipxl-300376233.html
SOURCE Kahn Swick & Foti, LLC
Copyright 2016 PR Newswire
1 Year Impax Laboratories, Inc. (delisted) Chart |
1 Month Impax Laboratories, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
